Minimal Residual Disease (MRD) Testing
News and reporting on minimal residual disease testing.
Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials
MPAACT members will share trial data, aiming to standardize measurable residual disease as a surrogate endpoint for overall survival and speed up drug development. Â
Genetron Health Nabs CE Mark for Blood Cancer Residual Disease Test Kit
The assay uses the company's "One-step Seq" method to detect cancer-associated DNA sequences in bone marrow from patients with certain hematologic cancers.
Natera Minimal Residual Disease Test Value Called Into Question by City of Hope CRC Patient Data
Premium
Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.
Personalis Locks in Clinical Launch Plans as Oncology Testing Takes Lead Over Population Sequencing
Premium
As its research business increasingly tilts toward oncology, the firm has cemented plans for its first clinical test launch this year.
Invitae Launches Study to Generate Real-World Data on Personalized MRD Test Across Tumor Types
Premium
The 1,000-patient MARIA trial may provide insights into the types of cases for which oncologists are willing to use Invitae's test to track recurrence and guide treatment.